A marketing authorization for Rhokiinsa, for the reduction of elevated IOP in open-angle glaucoma or ocular hypertension, has been approved by the European Commission, according to a press release.
Known as Rhopressa in the United States, Rhokiinsa (netarsudil ophthalmic solution 0.02%, Aerie Pharmaceuticals) was accepted for review by the European Medicines Agency in October 2018 and received a positive scientific opinion recommending approval from the EMA’s Committee for Medicinal Products for Human Use earlier this year.
“Importantly, this approval also sets the stage for our
Uncategorized